SEC Form 4 · accession 0001250853-18-000041
Kindred Biosciences, Inc. · KIN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Raymond Townsend
Director
Period of report
Mar 12, 2018
Accepted (ET)
Mar 14, 2018 · 8:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001561743
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 12, 2018 | M | 91 | $3.45 | A | 23,233 | D | |
| Common Stock | Mar 12, 2018 | S | 91 | $9.45 | D | 23,142 | D | |
| Common Stock | Mar 12, 2018 | M | 155 | $3.45 | A | 23,297 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $3.45 | Mar 12, 2018 | M | 91 | D | — | Jan 8, 2026 | Common Stock | 91 | 26,348 | D |
| Stock Option (right to buy)F2 | $3.45 | Mar 12, 2018 | M | 155 | D | — | Jan 8, 2026 | Common Stock | 155 | 26,193 | D |
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2017.
- F2The option vested 25% quarterly following January 8, 2016, the date of grant.